Acid-Base Disorders

Quick Answer

Acid-base disorders are common in critically ill patients and require systematic analysis for accurate diagnosis and management. The normal arterial pH is 7.35-7.45, maintained by respiratory (PaCO2) and metabolic (HCO3-) buffering systems. A systematic approach involves: (1) Assess pH to determine acidemia or alkalemia, (2) Identify the primary disorder (respiratory vs metabolic), (3) Calculate the anion gap (AG = Na - [Cl + HCO3], normal 8-12 mEq/L), (4) Assess compensation using Winter's formula (expected PaCO2 = 1.5 × HCO3 + 8 ± 2), and (5) Calculate the delta ratio to identify mixed disorders. High anion gap metabolic acidosis (HAGMA) is remembered by the MUDPILES mnemonic (Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates). Normal anion gap metabolic acidosis (NAGMA) results from bicarbonate loss (diarrhea) or impaired renal acid excretion (RTA). The BICAR-ICU trial (PMID: 29910040) demonstrated that sodium bicarbonate in severe metabolic acidemia (pH ≤7.20) with AKI reduces mortality (46% vs 63%, p=0.016) and RRT requirements. The Stewart approach provides a physicochemical framework using strong ion difference (SID), weak acids (ATOT), and PCO2 as independent variables. Lactate is classified as Type A (hypoperfusion: sepsis, shock, cardiac arrest) or Type B (impaired metabolism: metformin, propofol infusion syndrome, malignancy, thiamine deficiency).

---

CICM Exam Focus

Key High-Yield Points

1. Systematic Approach: pH → Primary disorder → Anion gap → Compensation → Delta ratio
2. Anion Gap Calculation: AG = Na - (Cl + HCO3), normal 8-12 mEq/L; albumin-corrected AG adds 2.5 for every 10 g/L albumin below 40
3. Winter's Formula: Expected PaCO2 = (1.5 × HCO3) + 8 ± 2 for metabolic acidosis compensation
4. Delta Ratio: (ΔAG)/(ΔHCO3) = (AG - 12)/(24 - HCO3); ratio greater than 2 indicates concurrent metabolic alkalosis
5. BICAR-ICU Trial: Bicarbonate improves survival in severe acidemia (pH ≤7.20) with AKI (PMID: 29910040)
6. Stewart Approach: SID (strong ion difference), ATOT (weak acids), PCO2 as independent variables
7. Lactate Classification: Type A (hypoperfusion) vs Type B (impaired metabolism/clearance)
8. Compensation Rules: Acute vs chronic respiratory compensation (1 vs 3.5-4 mEq/L per 10 mmHg PCO2)

Common Viva Themes

• Systematic interpretation of ABG in complex ICU patient
• Differential diagnosis of high anion gap metabolic acidosis
• Indications for bicarbonate therapy in metabolic acidosis
• Stewart approach vs traditional Henderson-Hasselbalch
• Lactate as a resuscitation marker and prognostic indicator
• Mixed acid-base disorders (triple acid-base disturbance)
• Management of metabolic alkalosis in the ventilated patient
• Hyperchloremic acidosis from saline resuscitation

Common Pitfalls

• Forgetting to correct the anion gap for albumin (very common in ICU patients)
• Not recognizing a concurrent metabolic alkalosis masked by HAGMA (check delta ratio)
• Confusing compensation with a second primary disorder
• Over-treating metabolic acidosis with bicarbonate without addressing the underlying cause
• Failing to identify Type B lactic acidosis (drug-related) in the presence of normal hemodynamics
• Ignoring the respiratory component in mixed disorders
• Not recognizing post-hypercapnic metabolic alkalosis after correcting chronic respiratory acidosis

---

Key Points

• Normal arterial pH 7.35-7.45; acidemia below 7.35, alkalemia greater than 7.45
• Anion gap = Na - (Cl + HCO3); normal 8-12 mEq/L; correct for albumin (+2.5 per 10 g/L below 40)
• HAGMA: MUDPILES mnemonic (Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates)
• NAGMA: GI bicarbonate loss (diarrhea), RTA types 1/2/4, saline resuscitation (hyperchloremic)
• Winter's formula: Expected PaCO2 = (1.5 × HCO3) + 8 ± 2 for metabolic acidosis
• Delta ratio: (AG-12)/(24-HCO3); below 0.4 NAGMA, 1-2 pure HAGMA, greater than 2 HAGMA + metabolic alkalosis
• BICAR-ICU: Bicarbonate in severe acidemia with AKI reduces mortality (46% vs 63%) and RRT need
• Stewart approach: pH determined by SID (normal ~40 mEq/L), ATOT (albumin, phosphate), and PCO2
• Type A lactic acidosis: Tissue hypoxia/hypoperfusion (sepsis, shock, cardiac arrest)
• Type B lactic acidosis: Impaired metabolism (metformin, propofol, malignancy, thiamine deficiency)
• Metabolic alkalosis: Chloride-responsive (vomiting, diuretics) vs chloride-resistant (hyperaldosteronism)
• Respiratory acidosis: Acute (HCO3 ↑1 per PCO2 ↑10) vs chronic (HCO3 ↑3.5 per PCO2 ↑10)

---

Physiology of Acid-Base Homeostasis

Normal Acid-Base Balance

The human body maintains arterial pH within a narrow range of 7.35-7.45 through multiple buffering systems and organ-based compensatory mechanisms. Daily acid production from metabolism generates approximately 50-100 mmol of non-volatile acids (primarily sulfuric acid from protein metabolism) and 15,000-20,000 mmol of volatile acid (CO2 from cellular respiration). [1]

The three principal buffering systems include:

Bicarbonate-Carbonic Acid System (Primary): The most important extracellular buffer, described by the Henderson-Hasselbalch equation:

pH = 6.1 + log([HCO3-]/[0.03 × PaCO2])

Normal values: HCO3- = 22-26 mmol/L, PaCO2 = 35-45 mmHg, giving pH 7.35-7.45.

Hemoglobin and Intracellular Proteins: Histidine residues on hemoglobin and intracellular proteins buffer approximately 60% of CO2 generated in tissues. The deoxygenation of hemoglobin enhances its buffering capacity (Haldane effect). [2]

Phosphate Buffer System: Important in renal tubular fluid and intracellular compartments where phosphate concentrations are higher than in plasma.

Respiratory Compensation

The respiratory system responds rapidly to acid-base disturbances through changes in alveolar ventilation:

• Metabolic acidosis: Increased minute ventilation (Kussmaul respirations) reduces PaCO2 within minutes to hours
• Metabolic alkalosis: Hypoventilation raises PaCO2, though this is limited by the drive to maintain oxygenation

Compensation Rules for Respiratory Acidosis/Alkalosis: [3]

Chronic compensation requires 3-5 days to develop fully, driven by renal mechanisms.

Renal Compensation

The kidneys are the primary organs for non-volatile acid excretion and bicarbonate regeneration:

Bicarbonate Reabsorption: The proximal tubule reabsorbs 80-90% of filtered bicarbonate via Na+/H+ exchange and carbonic anhydrase activity. The thick ascending limb and collecting duct reclaim the remainder.

Acid Excretion: Titratable acids (primarily phosphate) and ammonium (NH4+) excretion in the collecting duct regenerate bicarbonate. In acidosis, renal ammoniagenesis increases over days, allowing greater acid excretion.

Compensation for Metabolic Disorders: [4]

---

Systematic Approach to Acid-Base Analysis

Step 1: Assess the pH

Acidemia: pH < 7.35 Alkalemia: pH > 7.45 Normal pH with abnormal PaCO2/HCO3: Suggests complete compensation or mixed disorder

A normal pH with abnormal PaCO2 and HCO3 should raise suspicion for a mixed disorder where opposing processes cancel each other. [5]

Step 2: Identify the Primary Disorder

If pH < 7.35 (Acidemia):

• PaCO2 > 45 mmHg → Respiratory acidosis
• HCO3 < 22 mmol/L → Metabolic acidosis

If pH > 7.45 (Alkalemia):

• PaCO2 < 35 mmHg → Respiratory alkalosis
• HCO3 > 26 mmol/L → Metabolic alkalosis

Step 3: Calculate the Anion Gap

The anion gap represents unmeasured anions in the plasma:

Anion Gap = Na - (Cl + HCO3)

Normal range: 8-12 mEq/L (may vary slightly by laboratory)

Albumin Correction: In hypoalbuminemia (extremely common in ICU patients), the "normal" anion gap is reduced. For every 10 g/L decrease in albumin below 40 g/L, the normal AG decreases by 2.5 mEq/L. [6]

Corrected AG = Observed AG + 2.5 × (40 - albumin)/10

Example: Patient with albumin 20 g/L and AG 12: Corrected AG = 12 + 2.5 × (40-20)/10 = 12 + 5 = 17 (elevated, suggesting HAGMA)

Step 4: Assess Appropriateness of Compensation

Winter's Formula for Metabolic Acidosis:

Expected PaCO2 = (1.5 × HCO3) + 8 ± 2

• If measured PaCO2 > expected: Concurrent respiratory acidosis
• If measured PaCO2 < expected: Concurrent respiratory alkalosis

Alternative "Last Two Digits" Rule: In simple metabolic acidosis, the PaCO2 should approximate the last two digits of the pH (e.g., pH 7.25 → PaCO2 ~25 mmHg).

Compensation Limits: The respiratory system rarely achieves PaCO2 < 10-15 mmHg even in severe metabolic acidosis due to work of breathing limitations.

Step 5: Calculate the Delta Ratio

The delta ratio (Δ/Δ or "gap-gap") identifies hidden metabolic disorders:

Delta Ratio = (AG - 12) / (24 - HCO3)

Clinical Significance: A ratio greater than 2 indicates that bicarbonate is higher than expected for the degree of anion gap elevation, suggesting a coexisting metabolic alkalosis (e.g., patient with DKA who has also been vomiting). [7]

Step 6: Strong Ion Gap (Stewart Approach)

For complex cases, the Strong Ion Gap (SIG) identifies unmeasured anions more accurately:

SIG = SIDa - SIDe

Where:

• SIDa (apparent) = Na + K + Ca + Mg - Cl - lactate
• SIDe (effective) = calculated from HCO3, albumin, and phosphate

A positive SIG indicates unmeasured strong anions (similar to elevated anion gap). Normal SIG is approximately 0. [8]

---

High Anion Gap Metabolic Acidosis (HAGMA)

MUDPILES Mnemonic

High anion gap metabolic acidosis results from accumulation of acids that provide unmeasured anions:

GOLD MARK Alternative Mnemonic: Glycols, Oxoproline (pyroglutamic acid from acetaminophen), L-lactate, D-lactate, Methanol, Aspirin, Renal failure, Ketoacidosis. [9]

Lactic Acidosis

Lactate is the most common cause of HAGMA in critically ill patients. Normal serum lactate is 0.5-1.5 mmol/L. Hyperlactatemia is defined as greater than 2 mmol/L, and lactic acidosis as greater than 4 mmol/L with pH below 7.35. [10]

Cohen-Woods Classification: [11]

Type A (Tissue Hypoperfusion/Hypoxia): The most common type in ICU

• Sepsis and septic shock
• Cardiogenic shock
• Hypovolemic shock
• Cardiac arrest
• Severe anemia
• Carbon monoxide poisoning
• Regional hypoperfusion (mesenteric ischemia, limb ischemia)

Type B (No Evidence of Tissue Hypoxia):

Type B1 - Associated with underlying disease:

• Liver failure (impaired lactate clearance)
• Malignancy (Warburg effect: aerobic glycolysis)
• Thiamine deficiency (impaired pyruvate dehydrogenase)
• Pheochromocytoma

Type B2 - Drug/toxin-induced:

• Metformin (mitochondrial complex I inhibition)
• Propofol (propofol infusion syndrome - fatty acid oxidation inhibition)
• Nucleoside reverse transcriptase inhibitors (NRTIs)
• Linezolid (mitochondrial toxicity)
• Salicylates (uncoupling of oxidative phosphorylation)

Type B3 - Inborn errors of metabolism:

• Pyruvate dehydrogenase deficiency
• Mitochondrial myopathies

Metformin-Associated Lactic Acidosis (MALA)

MALA is a Type B2 lactic acidosis occurring in metformin users, typically triggered by acute kidney injury that impairs metformin clearance. [12]

Pathophysiology:

• Metformin inhibits mitochondrial complex I
• Decreased oxidative phosphorylation shifts metabolism toward anaerobic glycolysis
• Inhibition of hepatic gluconeogenesis from lactate compounds the problem

Clinical Features:

• Severe acidosis (pH often below 7.0)
• Very high lactate (often greater than 10-15 mmol/L)
• Often better prognosis than Type A acidosis of similar severity if treated promptly

Management:

• Discontinue metformin
• Supportive care (intubation, vasopressors)
• Renal replacement therapy (hemodialysis) for metformin clearance and pH correction
• Sodium bicarbonate for severe acidemia (controversial but commonly used)

Propofol Infusion Syndrome (PRIS)

PRIS is a rare but potentially fatal complication of prolonged propofol infusion, characterized by severe lactic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure, and Brugada-like ECG changes. [13]

Risk Factors:

• High dose (greater than 4-5 mg/kg/h)
• Prolonged duration (greater than 48 hours)
• Critical illness (especially children, TBI)
• Catecholamine or corticosteroid co-administration
• Mitochondrial disease

Pathophysiology:

• Propofol impairs mitochondrial fatty acid oxidation
• Uncoupling of oxidative phosphorylation
• Impaired electron transport chain

Management:

• Immediate cessation of propofol
• Alternative sedation (dexmedetomidine, benzodiazepines, opioids)
• Supportive care (glucose/dextrose, treat hyperkalemia)
• ECMO in refractory cardiac failure (salvage)
• Mortality greater than 50% in established PRIS

D-Lactic Acidosis

D-lactic acidosis is an under-recognized cause of HAGMA that occurs in patients with short bowel syndrome or jejunoileal bypass when carbohydrates are fermented by gut bacteria into D-lactate. [14]

Key Features:

• High anion gap with NORMAL L-lactate (standard assays measure only L-lactate)
• Neurological symptoms: ataxia, slurred speech, confusion (mimics alcohol intoxication)
• Triggered by high carbohydrate intake

Diagnosis: Requires specific D-lactate assay (not routine)

Management:

• Stop enteral carbohydrates
• Oral antibiotics (vancomycin, metronidazole) to reduce D-lactate-producing bacteria
• Bicarbonate or hemodialysis for severe acidosis

Diabetic Ketoacidosis (DKA)

DKA is characterized by the triad of hyperglycemia, ketosis, and metabolic acidosis due to insulin deficiency and counter-regulatory hormone excess. [15]

Diagnostic Criteria:

• Blood glucose greater than 11 mmol/L (may be lower in euglycemic DKA with SGLT2 inhibitors)
• pH below 7.30 and/or HCO3 below 18 mmol/L
• Ketonemia (β-hydroxybutyrate greater than 3 mmol/L) or ketonuria

Severity Classification:

Management Principles:

1. Fluid resuscitation (0.9% saline initially)
2. Insulin infusion (0.1 units/kg/h after K+ confirmed greater than 3.3)
3. Potassium replacement (target 4-5 mmol/L)
4. Monitor and treat precipitant (infection, non-compliance)
5. Transition to SC insulin when eating, pH greater than 7.30, AG normalized

Toxic Alcohols (Methanol, Ethylene Glycol)

Methanol Poisoning: Methanol is metabolized by alcohol dehydrogenase to formaldehyde and then formate, which inhibits cytochrome oxidase and causes severe HAGMA. [16]

Clinical features:

• Visual disturbances ("snowstorm" vision, blindness)
• Severe acidosis with high anion gap
• Osmolar gap initially (unmeasured methanol), then AG rises as formate accumulates

Management:

• Fomepizole or ethanol (inhibit alcohol dehydrogenase)
• Hemodialysis for methanol greater than 50 mg/dL, visual symptoms, or pH below 7.15
• Folinic acid (enhances formate metabolism)

Ethylene Glycol Poisoning: Metabolized to glycolic and oxalic acids, causing HAGMA and acute kidney injury from calcium oxalate crystal deposition. [17]

Clinical features:

• CNS depression (intoxication)
• Cardiopulmonary effects (24-72 hours)
• Acute kidney injury (crystalluria, flank pain)
• Calcium oxalate crystals on urinalysis

Management:

• Fomepizole or ethanol
• Hemodialysis for ethylene glycol greater than 50 mg/dL, renal failure, or pH below 7.15
• Pyridoxine and thiamine (promote non-toxic metabolism)

Salicylate Toxicity

Salicylate poisoning produces a unique mixed acid-base disorder: primary respiratory alkalosis (direct stimulation of respiratory center) AND primary metabolic acidosis (uncoupling of oxidative phosphorylation). [18]

Clinical Features:

• Tinnitus, hearing loss
• Hyperthermia, diaphoresis
• Altered mental status (severe toxicity)
• Non-cardiogenic pulmonary edema

Management:

• Activated charcoal if recent ingestion
• IV sodium bicarbonate to maintain urine pH 7.5-8.0 (ion trapping)
• Hemodialysis for levels greater than 100 mg/dL, altered mental status, pulmonary edema, renal failure
• Avoid intubation if possible (risk of precipitous decline if hyperventilation lost)

---

Normal Anion Gap Metabolic Acidosis (NAGMA)

NAGMA, also called hyperchloremic metabolic acidosis, occurs when bicarbonate loss is balanced by reciprocal chloride retention to maintain electroneutrality.

Classification

Gastrointestinal Bicarbonate Loss:

• Diarrhea (most common cause)
• Pancreatic or biliary fistulas
• Ureterosigmoidostomy

Renal Causes:

• Renal tubular acidosis (Types 1, 2, 4)
• Early chronic kidney disease
• Carbonic anhydrase inhibitors (acetazolamide)

Iatrogenic:

• Saline resuscitation (hyperchloremic acidosis)
• Parenteral nutrition (arginine, lysine)

Urinary Anion Gap

The urinary anion gap (UAG) helps differentiate GI from renal causes:

UAG = Urine Na + Urine K - Urine Cl

• Negative UAG (e.g., -20 to -50): Normal renal acidification; suggests GI loss (diarrhea)
• Positive UAG (e.g., +10 to +30): Impaired renal ammonium excretion; suggests RTA

In diarrhea, the kidneys appropriately excrete NH4+ (unmeasured cation) with Cl-, making the UAG negative. In RTA, the kidney cannot excrete acid, so NH4+ excretion is low, making UAG positive. [19]

Renal Tubular Acidosis

Type 1 (Distal RTA): [20]

• Defective H+ secretion in collecting duct
• Urine pH inappropriately high (greater than 5.5) despite systemic acidosis
• Hypokalemia (K+ wasted to maintain electrical neutrality)
• Nephrocalcinosis and nephrolithiasis common
• Causes: Sjögren syndrome, SLE, amphotericin B, lithium

Type 2 (Proximal RTA):

• Defective HCO3- reabsorption in proximal tubule
• Urine pH below 5.5 when serum HCO3 stabilizes below threshold (~15 mmol/L)
• Hypokalemia
• Often associated with Fanconi syndrome (glycosuria, phosphaturia, aminoaciduria)
• Causes: Multiple myeloma, carbonic anhydrase inhibitors, ifosfamide

Type 4 (Hyperkalemic RTA):

• Aldosterone deficiency or resistance
• HYPERKALEMIA (distinguishing feature)
• Urine pH below 5.5 (can acidify urine)
• Causes: Diabetic nephropathy (most common), ACE inhibitors, K+-sparing diuretics, Addison disease

Saline-Induced Hyperchloremic Acidosis

Large-volume resuscitation with 0.9% normal saline is a common cause of NAGMA in the ICU. Normal saline has a chloride concentration of 154 mmol/L, significantly higher than physiological plasma chloride (100-106 mmol/L). [21]

Mechanism (Stewart Approach):

• Normal saline has a SID of 0 (Na+ 154 - Cl- 154)
• Infusion dilutes the patient's SID toward 0
• Lower SID causes water dissociation to release H+, lowering pH

Clinical Impact:

• Usually transient and well-tolerated
• The SMART and SALT-ED trials suggest balanced crystalloids (Plasma-Lyte, Hartmann's) reduce AKI compared to saline, though mortality differences are small (PMID: 29485925)

Prevention: Use balanced crystalloids for large-volume resuscitation when possible

---

Metabolic Alkalosis

Metabolic alkalosis is characterized by elevated pH (greater than 7.45) and HCO3- (greater than 26 mmol/L). It is the most common acid-base disturbance in hospitalized patients and is associated with increased mortality in critically ill patients. [22]

Classification: Chloride-Responsive vs Chloride-Resistant

Chloride-Responsive (Urine Cl- below 20 mmol/L): [23]

• Volume contraction and chloride depletion
• Responds to saline administration

Causes:

• Vomiting and nasogastric suction (loss of HCl)
• Diuretics (loop, thiazide) - after discontinuation
• Contraction alkalosis
• Post-hypercapnic alkalosis

Chloride-Resistant (Urine Cl- greater than 40 mmol/L):

• Mineralocorticoid excess or renal chloride wasting
• Does NOT respond to saline

Causes:

• Primary hyperaldosteronism (Conn syndrome)
• Cushing syndrome
• Bartter and Gitelman syndromes
• Current diuretic use
• Licorice ingestion (apparent mineralocorticoid excess)
• Liddle syndrome

Pathophysiology of Metabolic Alkalosis

Initiation Phase: Generation of alkalosis

• Loss of gastric HCl (vomiting, NG suction)
• Renal HCO3- generation (diuretics, mineralocorticoid excess)
• Alkali administration

Maintenance Phase: Why alkalosis persists

• Volume depletion stimulates proximal HCO3- reabsorption
• Chloride depletion limits HCO3- excretion (pendrin transporter requires Cl-)
• Hypokalemia stimulates H+ secretion
• Aldosterone stimulates H+ secretion in collecting duct

Clinical Features

Metabolic alkalosis is often well-tolerated but can cause:

• Neuromuscular irritability (hypokalemia-related)
• Arrhythmias (especially with hypokalemia)
• Hypoventilation (respiratory compensation increases PaCO2)
• Impaired oxygen unloading (left shift of oxyhemoglobin curve)
• Seizures (severe alkalemia reduces ionized calcium)

Management

Chloride-Responsive Alkalosis:

1. Volume repletion with 0.9% saline
2. Potassium chloride replacement
3. Stop offending medications (diuretics, proton pump inhibitors)
4. H2 receptor blockers or PPIs to reduce gastric acid secretion if ongoing losses

Chloride-Resistant Alkalosis:

1. Treat underlying cause (surgery for aldosteronoma)
2. Potassium-sparing diuretics (spironolactone, amiloride)
3. Potassium replacement

Refractory Metabolic Alkalosis:

• Acetazolamide 250-500 mg IV (promotes renal HCO3- excretion)
• Hydrochloric acid infusion (0.1N HCl via central line) for severe cases
• Hemodialysis with low-bicarbonate dialysate

Post-Hypercapnic Metabolic Alkalosis: [24] After rapid correction of chronic respiratory acidosis (e.g., intubation for COPD), the elevated HCO3- that was compensating persists temporarily. Management:

• Gradual reduction of minute ventilation
• Avoid over-correction of PaCO2
• Chloride and potassium replacement
• Acetazolamide if severe

---

Respiratory Acidosis

Respiratory acidosis results from alveolar hypoventilation leading to CO2 retention (PaCO2 greater than 45 mmHg). [25]

Causes

CNS Depression:

• Sedatives (opioids, benzodiazepines, propofol)
• General anesthesia
• Brainstem lesions
• Encephalopathy

Neuromuscular Disease:

• Myasthenia gravis
• Guillain-Barré syndrome
• Critical illness polyneuropathy/myopathy
• Spinal cord injury

Chest Wall/Pleural Disease:

• Severe kyphoscoliosis
• Morbid obesity (obesity hypoventilation syndrome)
• Flail chest
• Massive pleural effusion

Airway/Lung Disease:

• COPD exacerbation
• Severe asthma
• Upper airway obstruction
• End-stage pulmonary fibrosis

Acute vs Chronic Respiratory Acidosis

Acute (minutes to hours):

• Compensation via intracellular buffering only
• HCO3 increases by 1 mEq/L per 10 mmHg rise in PaCO2
• pH significantly decreased

Chronic (days to weeks):

• Renal compensation: increased HCO3 reabsorption and acid excretion
• HCO3 increases by 3.5-4 mEq/L per 10 mmHg rise in PaCO2
• pH near-normal (7.32-7.38)

Acute-on-Chronic: Common in COPD exacerbations. Chronic baseline compensation with acute worsening. pH drop is greater than expected for the PaCO2 increase.

Management

1. Treat underlying cause (bronchodilators for COPD, reversal agents for overdose)
2. Non-invasive ventilation: First-line for COPD exacerbations (PMID: 12617011)
3. Invasive mechanical ventilation: For severe cases, failure of NIV, or reduced consciousness
4. Avoid rapid correction in chronic hypercapnia: Risk of post-hypercapnic alkalosis and seizures

Oxygen Therapy in COPD: Target SpO2 88-92%. Excessive oxygen can worsen hypercapnia via:

• Loss of hypoxic respiratory drive
• Haldane effect (oxygenated Hb binds less CO2)
• V/Q mismatch (release of hypoxic pulmonary vasoconstriction)

---

Respiratory Alkalosis

Respiratory alkalosis results from alveolar hyperventilation leading to decreased PaCO2 (below 35 mmHg). [26]

Causes

Central Stimulation:

• Anxiety, pain, fever
• CNS disorders (stroke, meningitis, encephalitis)
• Medications (salicylates, progesterone)
• Pregnancy (progesterone-mediated)
• High altitude

Hypoxemia-Driven:

• Pneumonia
• Pulmonary embolism
• Pulmonary edema
• High altitude

Metabolic/Systemic:

• Sepsis (early, before lactic acidosis develops)
• Liver failure (hyperammonemia, impaired progesterone clearance)
• Gram-negative sepsis

Iatrogenic:

• Mechanical over-ventilation
• Therapeutic hyperventilation (rarely, for raised ICP)

Clinical Features

• Lightheadedness, circumoral paresthesias, carpopedal spasm (tetany)
• Arrhythmias (hypokalemia from intracellular shift)
• Confusion, seizures (severe cases - cerebral vasoconstriction)

Respiratory Alkalosis in Sepsis: Often the earliest acid-base abnormality in sepsis, appearing before metabolic acidosis. Should prompt investigation for occult infection. (PMID: 26114135)

Respiratory Alkalosis in Liver Failure: Nearly universal in acute liver failure and advanced cirrhosis. Mechanisms include hyperammonemia stimulating the respiratory center and impaired clearance of progesterone. (PMID: 6061148)

Management

• Treat underlying cause (anxiolysis, antipyretics, treat sepsis)
• Adjust ventilator settings if iatrogenic
• Severe cases: sedation, rebreathing (paper bag) - rarely needed

---

The Stewart Approach

Principles

The Stewart (physicochemical) approach provides an alternative framework for understanding acid-base disorders based on fundamental principles of aqueous chemistry: electroneutrality and conservation of mass. [27]

Unlike the traditional Boston approach (Henderson-Hasselbalch), which views HCO3- and H+ as independent drivers of pH, the Stewart approach treats them as dependent variables determined by three independent variables:

1. PaCO2 (respiratory component)
2. Strong Ion Difference (SID) (metabolic component)
3. Total Weak Acids (ATOT) - primarily albumin and phosphate

Strong Ion Difference (SID)

The SID is the difference between fully dissociated cations (strong bases) and fully dissociated anions (strong acids):

SIDapparent = [Na+] + [K+] + [Ca2+] + [Mg2+] - [Cl-] - [Lactate]

Normal SID ≈ 40 mEq/L

SID and pH:

• Decreased SID (below 40) → Acidosis
• Increased SID (greater than 40) → Alkalosis

Examples:

• Saline resuscitation: Saline has SID = 0 (Na 154 - Cl 154). Infusion lowers plasma SID → acidosis
• Vomiting: Loss of Cl- increases SID → alkalosis
• Lactic acidosis: Accumulation of lactate anion decreases SID → acidosis

Total Weak Acids (ATOT)

ATOT consists primarily of albumin and phosphate:

Effect on pH:

• Decreased ATOT → Alkalosis (common in ICU - hypoalbuminemia)
• Increased ATOT → Acidosis (hyperphosphatemia in renal failure)

Clinical Implication: A patient with albumin 20 g/L has a baseline metabolic alkalosis. A "normal" pH in this patient may mask an underlying metabolic acidosis.

Strong Ion Gap (SIG)

The SIG identifies unmeasured anions (analogous to the anion gap):

SIG = SIDa - SIDe

Where SIDe (effective SID) is calculated from HCO3, albumin, and phosphate.

• SIG = 0 in health
• Positive SIG indicates unmeasured anions (ketoacids, toxins, sulfates)

Clinical Advantages

The Stewart approach explains several phenomena the traditional approach struggles with: [28]

1. Why saline causes acidosis: SID = 0 fluid lowers plasma SID
2. The "alkalosis of hypoalbuminemia": Recognized and quantified
3. Complex ICU patients: Mathematical framework for multi-organ failure with multiple electrolyte derangements

Limitations

• Complex calculations at the bedside
• May not change clinical management compared to simpler approaches
• Requires additional laboratory values (albumin, phosphate)

For CICM examinations, understanding both traditional and Stewart approaches is essential.

---

Lactate in Critical Care

Lactate Metabolism

Lactate is produced from pyruvate by lactate dehydrogenase (LDH) during anaerobic glycolysis. Normal production is approximately 1,500 mmol/day, with lactate cleared primarily by the liver (60%) and kidneys (30%). [29]

Normal serum lactate: 0.5-1.5 mmol/L Hyperlactatemia: greater than 2 mmol/L Lactic acidosis: greater than 4 mmol/L with pH below 7.35

Type A vs Type B Lactic Acidosis

See HAGMA section for detailed classification. Key distinction:

• Type A: Oxygen delivery insufficient for demand (shock, hypoxia)
• Type B: Impaired oxygen utilization despite adequate delivery (mitochondrial dysfunction)

Lactate as a Resuscitation Marker

Serial lactate measurements guide resuscitation in sepsis and shock. Lactate clearance (decrease of ≥10-20% per 2 hours) is associated with improved outcomes. [30]

ANDROMEDA-SHOCK Trial (PMID: 30798570): Compared capillary refill time (CRT) vs lactate-guided resuscitation in septic shock. No significant mortality difference at 28 days, but CRT-guided resuscitation resulted in less organ dysfunction (SOFA score) and less fluid administration.

Surviving Sepsis Campaign 2021: Recommends targeting lactate normalization (rather than arbitrary targets) as part of resuscitation, though lactate should be interpreted in clinical context.

Lactate Clearance

Lactate clearance predicts outcomes:

• Clearance greater than 10% at 6 hours associated with improved survival
• Persistent hyperlactatemia despite resuscitation indicates ongoing tissue hypoxia or impaired clearance

Hepatic Impairment: Liver failure impairs lactate clearance. Elevated lactate in cirrhosis may reflect impaired clearance rather than tissue hypoxia.

Lactate in Cardiac Arrest

Post-cardiac arrest lactate reflects the severity of whole-body ischemia-reperfusion injury. High initial lactate (greater than 10 mmol/L) and poor clearance are associated with worse neurological outcomes. [31]

---

Bicarbonate Therapy

Controversy in Metabolic Acidosis

The use of sodium bicarbonate to treat metabolic acidosis has been controversial. Theoretical concerns include: [32]

• Paradoxical intracellular acidosis (CO2 generated crosses cell membranes faster than HCO3-)
• Volume overload (hypertonic solution)
• Hypernatremia
• Hypocalcemia (ionized calcium decreases with alkalosis)
• Overshoot alkalosis
• Hypokalemia (K+ shifts intracellularly)

The BICAR-ICU Trial

The BICAR-ICU trial (PMID: 29910040) is the landmark study addressing bicarbonate therapy in critically ill patients with severe metabolic acidemia. [33]

Study Design:

• 389 ICU patients with severe metabolic acidemia (pH ≤7.20, PaCO2 ≤45 mmHg, HCO3 ≤20 mmol/L, lactate ≥2 mmol/L)
• Randomized to 4.2% sodium bicarbonate (target pH 7.30) vs no bicarbonate
• Multi-center, open-label RCT in 26 French ICUs

Primary Outcome (composite of 28-day mortality + ≥1 organ failure at day 7):

• No significant difference overall: 66% bicarbonate vs 71% control (p=0.07)

Key Subgroup Finding - Acute Kidney Injury (AKIN 2-3):

• 28-day mortality significantly lower with bicarbonate: 46% vs 63% (p=0.016)
• Reduced need for RRT: 52% vs 62%
• Longer time to RRT initiation

Safety:

• More metabolic alkalosis, hypernatremia, and hypocalcemia in bicarbonate group
• No significant difference in hypervolemia or ventilator days

Clinical Implications:

• Routine bicarbonate for all metabolic acidemia is NOT supported
• Consider bicarbonate in severe acidemia (pH ≤7.20) with concurrent AKI
• Bicarbonate may reduce RRT requirements in this population

Indications for Bicarbonate Therapy

Generally Accepted Indications:

• Severe acidemia with hemodynamic instability
• Hyperkalemia with ECG changes (temporizing measure)
• Tricyclic antidepressant overdose (sodium channel blockade reversal)
• Salicylate poisoning (urinary alkalinization)
• Metabolic acidosis with AKI (based on BICAR-ICU)

NOT Recommended:

• Routine DKA management (unless pH below 6.9 or hemodynamic instability)
• Routine lactic acidosis from sepsis (focus on treating underlying cause)
• Cardiac arrest (no evidence of benefit; may worsen outcomes)

Dosing

If bicarbonate is indicated:

• Calculate bicarbonate deficit: (24 - measured HCO3) × 0.5 × body weight (kg)
• Give 50% of calculated deficit initially
• Target pH 7.20-7.30, not normalization
• Use 8.4% (1 mmol/mL) or 4.2% (0.5 mmol/mL) sodium bicarbonate
• Monitor pH, electrolytes, and ionized calcium frequently

---

Mixed Acid-Base Disorders

Triple Acid-Base Disorders

A triple disorder consists of three simultaneous primary acid-base disturbances, typically:

1. High anion gap metabolic acidosis (HAGMA)
2. Metabolic alkalosis
3. Respiratory acidosis OR respiratory alkalosis

Classic Scenario: COPD patient (chronic respiratory acidosis) with sepsis (HAGMA from lactic acidosis) who is also vomiting (metabolic alkalosis). [34]

Diagnostic Approach

1. Calculate the anion gap (corrected for albumin)
2. Check the delta ratio: ΔAG/ΔHCO3
   • Ratio greater than 2 suggests concurrent metabolic alkalosis
   • Ratio below 1 suggests concurrent NAGMA
3. Apply Winter's formula to detect respiratory component
4. Consider clinical context: What processes are active?

Example Analysis

Case: pH 7.42, PaCO2 42 mmHg, HCO3 26 mmol/L, Na 140, Cl 90, AG 24, Albumin 40 g/L

Analysis:

1. pH is normal - but AG is elevated (24), indicating HAGMA
2. ΔAG = 24 - 12 = 12
3. If pure HAGMA: HCO3 should drop by 12 (24 → 12). But HCO3 is 26.
4. Delta ratio = 12 / (24 - 26) = 12 / -2 (meaningless as HCO3 is ABOVE normal)
5. This indicates HAGMA + significant metabolic alkalosis (HCO3 higher than expected)
6. Expected PaCO2 for HCO3 of 26: Not applicable (alkalosis)
7. Diagnosis: Triple disorder - HAGMA (elevated AG) + metabolic alkalosis (HCO3 elevated despite HAGMA) + possible respiratory acidosis (PaCO2 inappropriately normal)

---

CICM Exam Practice

Short Answer Question 1: Systematic ABG Analysis

Question: A 58-year-old man with a history of COPD, diabetes mellitus, and chronic kidney disease stage 3B is admitted to ICU with community-acquired pneumonia. His arterial blood gas shows:

• pH 7.28
• PaCO2 58 mmHg
• HCO3 26 mmol/L
• Na 142 mmol/L
• K 5.8 mmol/L
• Cl 98 mmol/L
• Lactate 6.2 mmol/L
• Albumin 28 g/L

(a) Systematically analyze this arterial blood gas. (8 marks) (b) What is the likely clinical explanation for the acid-base disorder(s) identified? (4 marks) (c) Outline your initial management approach. (8 marks)

Model Answer:

(a) Systematic ABG Analysis:

Step 1 - pH Assessment: pH 7.28 indicates acidemia.

Step 2 - Primary Disorder:

• PaCO2 58 mmHg (elevated) → respiratory component contributing to acidosis
• HCO3 26 mmol/L (high-normal) → suggests chronic compensation or metabolic component

Step 3 - Anion Gap Calculation: AG = Na - (Cl + HCO3) = 142 - (98 + 26) = 18 mEq/L

Corrected AG for hypoalbuminemia: Corrected AG = 18 + 2.5 × (40 - 28)/10 = 18 + 3 = 21 mEq/L (elevated)

Step 4 - Assessment of Compensation: For acute respiratory acidosis: expected HCO3 = 24 + 1 × (58-40)/10 = 25.8 mmol/L For chronic respiratory acidosis: expected HCO3 = 24 + 3.5 × (58-40)/10 = 30.3 mmol/L

Measured HCO3 (26) is between acute and chronic, suggesting either partial chronicity or a superimposed metabolic process lowering HCO3.

Step 5 - Delta Ratio: ΔAG = 21 - 12 = 9 ΔHCO3 = 24 - 26 = -2 (HCO3 is above normal)

This is unusual - with HAGMA, HCO3 should be LOW. The fact that HCO3 is normal-high despite elevated AG suggests a concurrent metabolic alkalosis OR chronic respiratory compensation.

Step 6 - Interpretation: This patient has a triple acid-base disorder:

1. Acute-on-chronic respiratory acidosis: Baseline chronic hypercapnia from COPD with acute worsening from pneumonia
2. High anion gap metabolic acidosis: Corrected AG 21, likely from lactic acidosis (lactate 6.2)
3. Concurrent metabolic alkalosis or chronic respiratory compensation: HCO3 higher than expected for HAGMA

(b) Clinical Explanation:

The triple disorder is explained by:

1. Chronic respiratory acidosis with acute exacerbation: COPD provides baseline hypercapnia with renal compensation (elevated HCO3). Pneumonia has acutely worsened ventilation, further elevating PaCO2.
2. Lactic acidosis (Type A): Sepsis from pneumonia causing tissue hypoperfusion and anaerobic metabolism (lactate 6.2 mmol/L).
3. Chronic compensation: The elevated HCO3 (26) represents renal compensation for chronic hypercapnia. Without this, the pH would be much lower given the HAGMA and acute CO2 retention.

Alternatively, the patient may have received diuretics (chronic heart failure often coexists with COPD), contributing to metabolic alkalosis.

(c) Initial Management:

Respiratory Support:

• Supplemental oxygen targeting SpO2 88-92% (avoid excessive O2 in COPD)
• Non-invasive ventilation (BiPAP): First-line for acute-on-chronic respiratory failure in COPD with hypercapnia
• Settings: IPAP 12-15 cm H2O, EPAP 5 cm H2O, titrate to comfort and blood gas targets
• Intubation if NIV fails, severe encephalopathy, or hemodynamic instability

Sepsis Management:

• Blood cultures, sputum culture
• Empiric antibiotics for severe CAP (e.g., ceftriaxone + azithromycin OR benzylpenicillin + doxycycline per local guidelines)
• Fluid resuscitation with balanced crystalloid (Plasma-Lyte) - cautious volume given heart/renal disease
• Vasopressors if hypotensive despite fluid resuscitation (noradrenaline first-line)

Metabolic Correction:

• Treat underlying sepsis (antibiotics, source control)
• Monitor lactate clearance as resuscitation marker
• Bicarbonate therapy NOT routinely indicated unless pH below 7.15-7.20 with hemodynamic compromise or concurrent severe AKI (BICAR-ICU criteria)

Electrolyte Management:

• Hyperkalemia (K 5.8): ECG, consider calcium gluconate if ECG changes, insulin-dextrose, monitor closely
• Avoid potassium-sparing agents

Monitoring:

• Repeat ABG in 1-2 hours to assess response
• Serial lactate (target clearance greater than 10-20% per 2 hours)
• Continuous pulse oximetry
• Urine output (target greater than 0.5 mL/kg/h)

---

Short Answer Question 2: Bicarbonate Therapy in Metabolic Acidosis

Question: A 72-year-old woman with type 2 diabetes mellitus on metformin presents to the emergency department confused. Her investigations show:

• pH 6.98
• PaCO2 14 mmHg
• HCO3 3 mmol/L
• Lactate 22 mmol/L
• Creatinine 520 μmol/L (baseline 85 μmol/L)
• Metformin level: pending

(a) What is your diagnosis and the underlying mechanism? (6 marks) (b) Describe the key evidence regarding sodium bicarbonate therapy in metabolic acidosis. Reference the relevant trial. (8 marks) (c) Outline your specific management plan for this patient. (6 marks)

Model Answer:

(a) Diagnosis and Mechanism:

Diagnosis: Metformin-associated lactic acidosis (MALA) with acute kidney injury (KDIGO Stage 3).

Mechanism: Metformin inhibits mitochondrial complex I (NADH dehydrogenase) in the electron transport chain. This impairs oxidative phosphorylation, forcing cells to rely on anaerobic glycolysis for ATP production, generating lactate. Metformin also inhibits hepatic gluconeogenesis from lactate, further contributing to lactate accumulation.

In this patient, acute kidney injury (creatinine 520 vs baseline 85 μmol/L) has led to metformin accumulation (normally renally cleared), precipitating severe lactic acidosis. The very low pH (6.98) and extremely high lactate (22 mmol/L) are characteristic of MALA. Precipitants for AKI may include volume depletion (reduced oral intake), sepsis, or nephrotoxic medications.

The respiratory system is maximally compensating (PaCO2 14 mmHg), but cannot fully compensate for this severe metabolic acidosis. Using Winter's formula: expected PaCO2 = (1.5 × 3) + 8 = 12.5 ± 2 = 10.5-14.5 mmHg. The measured PaCO2 of 14 is appropriate, confirming simple metabolic acidosis with maximal respiratory compensation.

(b) Evidence for Sodium Bicarbonate Therapy:

BICAR-ICU Trial (Jaber et al., Lancet 2018, PMID: 29910040)

Design: Multicenter, open-label, randomized controlled phase 3 trial across 26 French ICUs. 389 ICU patients with severe metabolic acidemia (pH ≤7.20, PaCO2 ≤45 mmHg, HCO3 ≤20 mmol/L, lactate ≥2 mmol/L) were randomized to receive 4.2% sodium bicarbonate (targeting pH ≥7.30) or no bicarbonate (control).

Primary Outcome: Composite of 28-day all-cause mortality and presence of at least one organ failure at day 7. No significant difference was found in the overall population: 66% in bicarbonate group vs 71% in control (p=0.07).

Mortality: 28-day mortality was not significantly different overall (45% vs 54%).

Key Subgroup Finding (Pre-specified): In patients with Acute Kidney Injury (AKIN score 2-3) at enrollment:

• 28-day mortality was significantly LOWER with bicarbonate: 46% vs 63% (p=0.016)
• Survival was significantly higher (HR 0.57)
• Need for renal replacement therapy was reduced: 52% vs 62%
• Time to RRT initiation was prolonged

Safety Concerns: Bicarbonate group had higher rates of metabolic alkalosis, hypernatremia, and hypocalcemia. No significant difference in volume overload.

Interpretation: The BICAR-ICU trial does NOT support routine bicarbonate for all patients with metabolic acidemia. However, it provides evidence that bicarbonate therapy should be considered specifically for patients with severe acidemia (pH ≤7.20) AND concurrent acute kidney injury, where it may improve survival and reduce RRT requirements.

(c) Management Plan:

Immediate Resuscitation:

• Secure airway if GCS deteriorating (patient is confused)
• 100% oxygen via non-rebreather
• IV access (large bore × 2), arterial line
• Fluid resuscitation with balanced crystalloid (avoid saline - hyperchloremia)
• Vasopressor support (noradrenaline) if hypotensive despite fluids

Sodium Bicarbonate Therapy: Given pH 6.98 with concurrent severe AKI (AKIN 3), sodium bicarbonate is INDICATED based on BICAR-ICU trial findings:

• Calculate bicarbonate deficit: (24 - 3) × 0.5 × 70 kg = 735 mmol
• Give 50% initially (~370 mmol or 370 mL of 8.4%)
• Target pH 7.15-7.20 initially, then 7.30
• Monitor ionized calcium (will decrease with alkalosis)
• Monitor sodium (hypertonic solution)

Urgent Hemodialysis:

• Metformin is dialyzable (low molecular weight, minimal protein binding)
• Hemodialysis is the treatment of choice for MALA
• Indications met: severe refractory acidosis, AKI, drug toxicity requiring removal
• Use bicarbonate-based dialysate
• Continuous RRT (CVVHDF) if hemodynamically unstable

Supportive Care:

• ICU admission
• Discontinue metformin permanently (at least during this admission)
• Identify and treat precipitant of AKI
• Glucose monitoring (hypoglycemia risk in liver failure/impaired gluconeogenesis)
• Serial lactate (target clearance greater than 10% per 2 hours)
• Avoid nephrotoxins

Monitoring:

• Frequent ABGs (every 1-2 hours initially)
• Electrolytes (K+, Na+, iCa2+)
• Lactate clearance
• Hemodynamics
• Neurological status (GCS)

---

Viva Scenario 1: The Stewart Approach

Examiner: A 45-year-old woman is admitted to ICU with severe community-acquired pneumonia and septic shock. Her arterial blood gas shows pH 7.18, PaCO2 28 mmHg, HCO3 10 mmol/L, lactate 8 mmol/L. Her sodium is 140, chloride 112, potassium 4.5, albumin 18 g/L, phosphate 2.0 mmol/L.

Examiner: Can you analyze this blood gas using the traditional approach?

Candidate: Yes. This patient has acidemia with a pH of 7.18. The primary disorder is metabolic acidosis, indicated by the low bicarbonate of 10 mmol/L. The PaCO2 is 28 mmHg, which is low, suggesting respiratory compensation.

Using Winter's formula, the expected PaCO2 = (1.5 × 10) + 8 = 23 ± 2 mmHg. The measured PaCO2 of 28 is slightly higher than expected (23-25), suggesting there may be a mild concurrent respiratory acidosis - perhaps from respiratory muscle fatigue in severe sepsis.

The anion gap = 140 - (112 + 10) = 18 mEq/L, which appears normal-ish. However, I must correct for hypoalbuminemia. With albumin 18 g/L, the corrected anion gap = 18 + 2.5 × (40-18)/10 = 18 + 5.5 = 23.5 mEq/L - this is elevated, consistent with high anion gap metabolic acidosis from lactic acidosis.

Examiner: Good. Now explain the Stewart approach to this case.

Candidate: The Stewart approach uses three independent variables to determine pH:

1. PaCO2 - 28 mmHg (low, causing alkalosis if considered alone)

2. Strong Ion Difference (SID) - The apparent SID = [Na + K + Mg + Ca] - [Cl + lactate] Approximately = (140 + 4.5) - (112 + 8) = 144.5 - 120 = 24.5 mEq/L Normal SID is ~40 mEq/L. A SID of 24.5 is LOW, causing ACIDOSIS. This reduced SID is due to both hyperchloremia (Cl 112) and elevated lactate (8 mmol/L).

3. ATOT (weak acids) - Albumin 18 g/L is very low. This causes a baseline ALKALOSIS. With phosphate 2.0 mmol/L (assuming normal ~1.2), slightly elevated phosphate adds to acidosis, but the dominant effect is hypoalbuminemia causing alkalosis.

Interpreting the Stewart analysis:

• The low SID (24.5 vs normal 40) is the dominant abnormality, causing acidosis
• The hyperchloremia and hyperlactatemia both contribute to reduced SID
• Hypoalbuminemia creates a "hidden" alkalosis that partially offsets the acidosis
• The low PaCO2 represents respiratory compensation

This explains why the traditional anion gap appeared near-normal before correction - the hypoalbuminemia was masking the underlying acidosis.

Examiner: What is the Strong Ion Gap and how would you calculate it here?

Candidate: The Strong Ion Gap (SIG) identifies unmeasured strong anions, analogous to the anion gap but within the Stewart framework.

SIG = SIDapparent - SIDeffective

The SIDeffective is calculated from bicarbonate, albumin, and phosphate contributions: SIDe = HCO3 + (albumin contribution) + (phosphate contribution)

Using simplified calculations: SIDe ≈ 10 + [0.123 × pH - 0.631] × albumin + [0.309 × pH - 0.469] × phosphate

In health, SIG should be approximately zero. A positive SIG indicates unmeasured anions. In this patient, with lactate accounted for in the SIDa calculation, a positive SIG would suggest additional unmeasured anions such as ketoacids, sulfates, or toxic metabolites.

The clinical advantage is that Stewart's approach explicitly accounts for the common ICU finding of hypoalbuminemia, which the traditional approach may miss without correction.

Examiner: When would you prefer the Stewart approach over the traditional approach?

Candidate: I would consider the Stewart approach particularly valuable in:

1. Complex ICU patients with multiple organ failure and electrolyte derangements
2. Hypoalbuminemia - extremely common in critically ill patients, where traditional AG may be falsely reassuring
3. Hyperchloremic acidosis - Stewart explains the mechanism clearly (low SID from chloride excess)
4. Academic and teaching contexts - provides mechanistic understanding

However, for practical bedside use, the traditional approach with albumin-corrected anion gap is quicker and equally effective for most clinical decisions. The Stewart approach may not change management in most cases.

---

Viva Scenario 2: Lactate in Sepsis

Examiner: Tell me about lactate as a resuscitation marker in sepsis.

Candidate: Lactate is one of the most important biomarkers in sepsis management. It reflects tissue perfusion and cellular metabolism, and both initial levels and clearance have prognostic significance.

Elevated lactate in sepsis arises from several mechanisms:

1. Type A mechanism - tissue hypoperfusion and hypoxia causing anaerobic glycolysis
2. Aerobic lactate production - β-adrenergic stimulation increases glycolysis even with adequate oxygen
3. Impaired clearance - hepatic dysfunction reduces lactate metabolism
4. Mitochondrial dysfunction - sepsis impairs oxidative phosphorylation

Examiner: How do you use lactate clinically to guide resuscitation?

Candidate: I use lactate in several ways:

Initial Assessment: An elevated lactate (greater than 2 mmol/L) identifies patients at higher risk who need aggressive resuscitation. Lactate greater than 4 mmol/L indicates severe sepsis with significant tissue hypoperfusion.

Serial Monitoring: I measure lactate every 2-4 hours during resuscitation. The goal is lactate clearance of at least 10-20% over the first 6 hours.

Target Normalization: Rather than targeting a specific lactate value, I aim for a decreasing trend. The Surviving Sepsis Campaign 2021 recommends targeting lactate normalization as part of resuscitation.

Interpretation in Context: I don't treat the lactate in isolation. A falling lactate with improving clinical parameters (mental status, urine output, skin perfusion) indicates successful resuscitation. Persistent elevation despite apparent hemodynamic stability prompts me to consider Type B causes or ongoing occult hypoperfusion.

Examiner: What about the ANDROMEDA-SHOCK trial?

Candidate: The ANDROMEDA-SHOCK trial (PMID: 30798570) compared peripheral perfusion-targeted resuscitation using capillary refill time (CRT) versus lactate-targeted resuscitation in patients with septic shock.

Key Findings:

• Primary outcome (28-day mortality): No significant difference (34.9% CRT vs 43.4% lactate, p=0.06)
• Secondary outcomes favored CRT-guided approach:
  • Less organ dysfunction (lower SOFA scores at 72 hours)
  • Less fluid administered
  • Less vasopressor requirements

Interpretation: The trial suggests that clinical perfusion assessment (CRT below 3 seconds) is a valid and potentially superior alternative to lactate-guided resuscitation. It emphasizes that lactate is not the sole endpoint and clinical assessment remains crucial.

My Practice: I use both lactate and clinical parameters (CRT, mottling score, urine output, mental status) to guide resuscitation. I don't chase lactate if clinical perfusion is adequate, as persistent lactate may reflect Type B mechanisms or impaired clearance rather than ongoing tissue hypoxia.

Examiner: Discuss Type B lactic acidosis in the ICU.

Candidate: Type B lactic acidosis occurs without tissue hypoxia, due to impaired lactate metabolism or accelerated production. Important causes in the ICU include:

Drug-Induced (Type B2):

• Metformin: Most common. Inhibits mitochondrial complex I. Precipitated by AKI. Very high lactate levels possible. Hemodialysis is treatment of choice.
• Propofol Infusion Syndrome: High-dose (greater than 4 mg/kg/h) or prolonged (greater than 48h) infusion. Causes mitochondrial dysfunction, rhabdomyolysis, cardiac failure. High mortality. Stop propofol immediately.
• Nucleoside reverse transcriptase inhibitors (NRTIs): Mitochondrial toxicity.
• Linezolid: Mitochondrial toxicity with prolonged use.

Disease-Associated (Type B1):

• Liver failure: Impaired lactate clearance. Lactate may not reflect tissue perfusion.
• Malignancy: Warburg effect - cancer cells favor aerobic glycolysis. Common in hematologic malignancies.
• Thiamine deficiency: Impairs pyruvate dehydrogenase. Common in alcoholics, critically ill. Consider empiric thiamine in unexplained lactic acidosis.

Recognition: Type B acidosis should be suspected when lactate remains elevated despite restored hemodynamics and clinical perfusion. Drug history and comorbidities provide clues. Treatment targets the underlying cause rather than lactate directly.

---

References

1. Kellum JA. Disorders of acid-base balance. Crit Care Med. 2007;35(11):2630-2636. PMID: 17893626

2. Berend K, de Vries AP, Gans RO. Physiological approach to assessment of acid-base disturbances. N Engl J Med. 2014;371(15):1434-1445. PMID: 25295502

3. Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore). 1977;56(1):38-54. PMID: 401925

4. Albert MS, Dell RB, Winters RW. Quantitative displacement of acid-base equilibrium in metabolic acidosis. Ann Intern Med. 1967;66(2):312-322. PMID: 6016545

5. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162-174. PMID: 17699401

6. Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med. 1998;26(11):1807-1810. PMID: 9824071

7. Wrenn K. The delta (delta) gap: an approach to mixed acid-base disorders. Ann Emerg Med. 1990;19(11):1310-1313. PMID: 2240724

8. Kellum JA. Determinants of blood pH in health and disease. Crit Care. 2000;4(1):6-14. PMID: 10673331

9. Mehta AN, Emmett JB, Emmett M. GOLD MARK: an anion gap mnemonic for the 21st century. Lancet. 2008;372(9642):892. PMID: 18790314

10. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014;371(24):2309-2319. PMID: 25494270

11. Cohen RD, Woods HF. Clinical and biochemical aspects of lactic acidosis. Oxford: Blackwell Scientific Publications; 1976.

12. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016;65(2):20-29. PMID: 26773926

13. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122(4):448-459. PMID: 30857601

14. Petersen C. D-lactic acidosis. Nutr Clin Pract. 2005;20(6):634-645. PMID: 16306300

15. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. PMID: 19564476

16. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-446. PMID: 12216995

17. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008;3(1):208-225. PMID: 18045860

18. Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(2):95-131. PMID: 17364931

19. Batlle DC, Hizon M, Cohen E, Gutterman C, Gupta R. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988;318(10):594-599. PMID: 3344005

20. Yaxley J, Pirrone C. Review of the diagnostic evaluation of renal tubular acidosis. Ochsner J. 2016;16(4):525-530. PMID: 27999508

21. Self WH, Semler MW, Wanderer JP, et al. Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med. 2018;378(9):819-828. PMID: 29485926

22. Khanna A, Kurtzman NA. Metabolic alkalosis. J Nephrol. 2006;19 Suppl 9:S86-96. PMID: 16736447

23. Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol. 2012;23(2):204-207. PMID: 22223875

24. Epstein SK, Singh N. Respiratory acidosis. Respir Care. 2001;46(4):366-383. PMID: 11345943

25. Laffey JG, Kavanagh BP. Hypocapnia. N Engl J Med. 2002;347(1):43-53. PMID: 12097540

26. Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol. 1983;61(12):1444-1461. PMID: 6423247

27. Story DA. Bench-to-bedside review: a brief history of clinical acid-base. Crit Care. 2004;8(4):253-258. PMID: 15312208

28. Gibot S. On the origins of lactate during sepsis. Crit Care. 2012;16(5):151. PMID: 23017124

29. Jansen TC, van Bommel J, Schoonderbeek FJ, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182(6):752-761. PMID: 20463176

30. Donnino MW, Andersen LW, Giberson T, et al. Initial lactate and lactate change in post-cardiac arrest: a multicenter validation study. Crit Care Med. 2014;42(8):1804-1811. PMID: 24776606

31. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest. 2000;117(1):260-267. PMID: 10631227

32. Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018;392(10141):31-40. PMID: 29910040

33. Narins RG, Emmett M. Simple and mixed acid-base disorders: a practical approach. Medicine (Baltimore). 1980;59(3):161-187. PMID: 6766677

34. Hernandez G, Ospina-Tascon GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654-664. PMID: 30798570

35. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. PMID: 34599691

36. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(9):829-839. PMID: 29485925

37. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000;355(9219):1931-1935. PMID: 10859037

38. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817-822. PMID: 7651472

39. Fencl V, Jabor A, Kazda A, Figge J. Diagnosis of metabolic acid-base disturbances in critically ill patients. Am J Respir Crit Care Med. 2000;162(6):2246-2251. PMID: 11112147

40. Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol. 2001;12 Suppl 17:S15-19. PMID: 11251027

41. Gunnerson KJ, Saul M, He S, Kellum JA. Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Crit Care. 2006;10(1):R22. PMID: 16507145

---

Additional CICM Exam Practice

Viva Scenario 3: Metabolic Alkalosis in the ICU

Examiner: A 68-year-old man is mechanically ventilated in the ICU following major abdominal surgery. He has had significant nasogastric losses over the past 48 hours. His ABG shows pH 7.55, PaCO2 48 mmHg, HCO3 40 mmol/L. Serum K+ is 2.8 mmol/L, Cl- is 88 mmol/L, urine Cl- is 8 mmol/L.

Examiner: What is the acid-base disorder?

Candidate: This patient has a metabolic alkalosis with pH 7.55 and elevated HCO3 of 40 mmol/L. There is appropriate respiratory compensation with a mildly elevated PaCO2 of 48 mmHg. For metabolic alkalosis, the expected compensation is PaCO2 increase of approximately 0.7 mmHg per 1 mmol/L rise in HCO3, capped around 55 mmHg. With HCO3 40 (up 16 from normal), expected PaCO2 would be 40 + (0.7 × 16) = 51 mmHg. The measured 48 is slightly lower, suggesting possible mild concurrent respiratory alkalosis, but this could be within normal variation.

Examiner: What is the classification and likely cause?

Candidate: This is a chloride-responsive metabolic alkalosis based on the low urine chloride of 8 mmol/L (less than 20 mmol/L). The cause is clearly the significant nasogastric losses over 48 hours.

Mechanism: Loss of gastric HCl leads to generation of metabolic alkalosis. For every H+ ion secreted into the stomach by parietal cells, a HCO3- ion is generated and enters the blood. Normally this is balanced by pancreatic HCO3 secretion, but with nasogastric drainage, the H+ is lost and the bicarbonate load is not offset.

The alkalosis is maintained by:

1. Volume contraction - stimulates proximal tubule HCO3 reabsorption
2. Chloride depletion - the kidney cannot excrete HCO3 without chloride (pendrin exchanger)
3. Hypokalemia - promotes H+ secretion and HCO3 generation in the collecting duct
4. Secondary hyperaldosteronism - from volume depletion, further promotes H+ secretion

Examiner: How would you manage this patient?

Candidate: Management should address both the generation and maintenance phases of metabolic alkalosis:

1. Treat the underlying cause:

• Address ongoing gastric losses with proton pump inhibitor (pantoprazole 40 mg IV daily)
• Consider reducing NG drainage if clinically appropriate

2. Volume and chloride replacement:

• Intravenous 0.9% saline - provides both volume and chloride
• Target replacement of estimated fluid and chloride deficit
• Monitor fluid balance carefully in post-operative patient

3. Potassium replacement:

• Potassium chloride is preferred (provides both K+ and Cl-)
• Initial bolus 20-40 mmol IV KCl over 2-4 hours (via central line for higher concentrations)
• Target serum K+ 4.0-4.5 mmol/L
• Potassium repletion is essential - hypokalemia perpetuates alkalosis

4. Adjust ventilator settings:

• In severe alkalosis, may need to reduce minute ventilation to allow PaCO2 to rise
• However, must balance against underlying lung pathology
• Target pH normalization rather than aggressive PaCO2 manipulation

5. If refractory:

• Acetazolamide 250-500 mg IV - promotes renal HCO3 excretion
• Useful in patients with volume overload who cannot receive more saline
• Causes kaliuresis, so must replace potassium

6. Monitoring:

• Serial ABGs every 4-6 hours
• Electrolytes every 6-8 hours until stable
• Urine output and fluid balance

Examiner: What if this were a chloride-resistant metabolic alkalosis?

Candidate: Chloride-resistant metabolic alkalosis (urine Cl- greater than 40 mmol/L) would suggest:

• Primary hyperaldosteronism (Conn syndrome)
• Cushing syndrome
• Current diuretic use
• Bartter or Gitelman syndrome
• Licorice ingestion
• Liddle syndrome

Management would differ:

• Saline infusion would be ineffective
• Address underlying mineralocorticoid excess
• Spironolactone or amiloride for aldosterone antagonism
• Potassium replacement remains important
• Surgical treatment for aldosterone-producing adenoma

---

Viva Scenario 4: Toxic Alcohol Ingestion

Examiner: A 35-year-old man is brought to the emergency department by police after being found confused in a park. His ABG shows pH 7.15, PaCO2 18 mmHg, HCO3 6 mmol/L. Serum Na 140, K 4.5, Cl 102, glucose 5.5 mmol/L. His serum osmolality is 330 mOsm/kg.

Examiner: Analyze this blood gas.

Candidate: This patient has severe metabolic acidosis with pH 7.15 and HCO3 6 mmol/L. The PaCO2 is 18 mmHg, representing maximal respiratory compensation.

Using Winter's formula: expected PaCO2 = (1.5 × 6) + 8 = 17 ± 2 mmHg. The measured 18 is appropriate, confirming simple metabolic acidosis with appropriate compensation.

Anion gap = 140 - (102 + 6) = 32 mEq/L - this is severely elevated, indicating high anion gap metabolic acidosis.

Examiner: What about the osmolar gap?

Candidate: The osmolar gap is critical here and helps identify toxic alcohols.

Calculated serum osmolality = 2×Na + glucose + urea Assuming urea is normal (~5 mmol/L): 2×140 + 5.5 + 5 = 290.5 mOsm/kg

Osmolar gap = Measured osmolality - Calculated osmolality = 330 - 290.5 = 39.5 mOsm/kg

This is significantly elevated (normal below 10 mOsm/kg), indicating the presence of unmeasured osmoles - most likely a toxic alcohol.

Examiner: What are the differential diagnoses?

Candidate: The combination of high anion gap metabolic acidosis with elevated osmolar gap strongly suggests toxic alcohol ingestion:

1. Methanol poisoning - metabolized to formate

   • Classic features: visual disturbances (blurred vision, "snowstorm" appearance, blindness), CNS depression
   • Formate inhibits cytochrome oxidase

2. Ethylene glycol poisoning - metabolized to glycolate and oxalate

   • Classic features: CNS depression initially, cardiopulmonary toxicity at 12-24 hours, acute kidney injury (calcium oxalate crystals) at 24-72 hours
   • Calcium oxalate crystals on urinalysis

3. Propylene glycol toxicity - iatrogenic from IV medications (lorazepam, phenobarbital, nitroglycerin)

   • Metabolized to lactate
   • Usually occurs with high-dose prolonged infusions

4. Isopropyl alcohol - metabolized to acetone

   • Causes elevated osmolar gap but NOT metabolic acidosis (acetone is not an acid)
   • Sweet/fruity breath odor, ketones positive

The combination of elevated osmolar gap AND high anion gap acidosis essentially confirms methanol or ethylene glycol poisoning.

Examiner: How would you manage this patient?

Candidate: Management follows the principles for any toxic alcohol ingestion:

Immediate Stabilization:

• Secure airway if GCS deteriorating
• IV access, supplemental oxygen
• Cardiac monitoring

Antidote - Fomepizole or Ethanol:

• Fomepizole (preferred): Loading dose 15 mg/kg IV, then 10 mg/kg q12h
• If fomepizole unavailable: Ethanol infusion to maintain blood alcohol 100-150 mg/dL
• These agents inhibit alcohol dehydrogenase, preventing metabolism of parent compound to toxic metabolites

Hemodialysis - Indications:

• Toxic alcohol level greater than 50 mg/dL (if known)
• Severe metabolic acidosis (pH below 7.15)
• End-organ toxicity (visual symptoms in methanol, renal failure in ethylene glycol)
• This patient meets criteria with pH 7.15

Cofactor Therapy:

• Methanol: Folinic acid (leucovorin) 50-70 mg IV q4h - enhances formate metabolism
• Ethylene glycol: Thiamine 100 mg IV + Pyridoxine 50 mg IV q6h - promotes non-toxic metabolism

Bicarbonate:

• Consider if pH severely low - helps correct acidosis and reduces toxic metabolite entry to tissues
• However, dialysis is definitive

Other:

• Check specific toxic alcohol levels if available
• Ophthalmology consult for methanol (fundoscopy)
• Monitor renal function for ethylene glycol

---

Short Answer Question 3: Normal Anion Gap Metabolic Acidosis

Question: A 42-year-old woman with Crohn's disease and short bowel syndrome is admitted to ICU with confusion, ataxia, and slurred speech. Her arterial blood gas shows pH 7.25, PaCO2 28 mmHg, HCO3 12 mmol/L. Her sodium is 140 mmol/L, chloride 116 mmol/L, lactate (L-lactate assay) 1.2 mmol/L.

(a) What is the acid-base disturbance? Calculate the anion gap. (4 marks) (b) What is the most likely diagnosis and pathophysiology? (6 marks) (c) How would you confirm the diagnosis and what is the treatment? (6 marks) (d) What dietary advice should be given for prevention? (4 marks)

Model Answer:

(a) Acid-Base Disturbance:

The patient has metabolic acidosis with pH 7.25 and HCO3 12 mmol/L. The PaCO2 is 28 mmHg.

Expected PaCO2 (Winter's formula) = (1.5 × 12) + 8 = 26 ± 2 mmHg. Measured 28 is appropriate, confirming simple metabolic acidosis with adequate compensation.

Anion gap = Na - (Cl + HCO3) = 140 - (116 + 12) = 12 mEq/L

This is a normal anion gap metabolic acidosis (NAGMA) or hyperchloremic acidosis.

However, this is unusual because the clinical presentation (confusion, ataxia, slurred speech) suggests a toxic etiology that typically causes HAGMA. This discrepancy is the key diagnostic clue.

(b) Diagnosis and Pathophysiology:

The most likely diagnosis is D-lactic acidosis.

Key Clinical Clues:

• Short bowel syndrome (major risk factor)
• Neurological symptoms mimicking alcohol intoxication (confusion, ataxia, slurred speech)
• Normal anion gap with NORMAL L-lactate (standard assays only measure L-lactate)
• "Hidden" acidosis - the D-lactate is causing anion gap elevation but is not detected

Pathophysiology: In short bowel syndrome, unabsorbed carbohydrates reach the colon where they are fermented by bacteria (especially Lactobacillus, Bifidobacterium) producing D-lactate. Humans have limited ability to metabolize D-lactate because D-lactate dehydrogenase (D-LDH) has much lower activity than L-LDH.

The D-lactate accumulates, causing:

1. Metabolic acidosis
2. Neurological symptoms (D-lactate crosses the blood-brain barrier and causes encephalopathy)

The anion gap may appear normal because standard lactate assays only measure L-lactate. The "true" anion gap (if D-lactate were included) would be elevated.

(c) Diagnosis Confirmation and Treatment:

Diagnosis Confirmation:

• Specific D-lactate assay - must be specifically ordered (not part of routine L-lactate or ABG)
• D-lactate levels greater than 3 mmol/L are diagnostic (normal below 0.2 mmol/L)
• Clinical context: short bowel syndrome + neurological symptoms + metabolic acidosis with "normal" L-lactate

Treatment:

Immediate (Acute Episode):

1. NPO - stop all enteral/oral carbohydrates to starve D-lactate-producing bacteria
2. IV fluids - balanced crystalloid for hydration
3. Sodium bicarbonate - for severe acidosis (though controversial)
4. Hemodialysis - for severe or refractory acidosis, or profound neurological symptoms

Antibiotic Therapy (Reduce Bacterial Load):

• Oral non-absorbable antibiotics to reduce D-lactate-producing bacteria
• Options: Metronidazole 400 mg TID, or Vancomycin 125 mg QID orally, or Neomycin 500 mg QID
• Duration 7-14 days typically

Supportive:

• Thiamine supplementation (cofactor for pyruvate metabolism)
• Correct electrolyte abnormalities
• Neurological symptoms typically resolve within 24-48 hours of treatment

(d) Dietary Advice for Prevention:

Long-term Dietary Modifications:

1. Low carbohydrate diet - reduce substrate for bacterial fermentation

   • Avoid simple sugars, refined carbohydrates
   • Limit high-starch foods (bread, pasta, rice, potatoes)

2. Small, frequent meals - reduce carbohydrate load per meal

3. High-fat, high-protein diet - provides calories without excess carbohydrate

4. Avoid specific probiotics - particularly those containing Lactobacillus acidophilus or other D-lactate-producing species

5. Consider complex carbohydrates over simple sugars - slower absorption reduces colonic carbohydrate delivery

6. Adequate hydration - maintain normal bowel transit

7. Regular follow-up - with gastroenterology and dietitian for nutritional optimization

8. Patient education - recognize early symptoms (confusion, incoordination) as potential D-lactic acidosis and seek medical attention

---

Short Answer Question 4: Compensation Assessment

Question: For each of the following arterial blood gas results, determine whether compensation is appropriate or if there is a mixed disorder present. Show your calculations.

(a) pH 7.32, PaCO2 25 mmHg, HCO3 12 mmol/L

(b) pH 7.52, PaCO2 48 mmHg, HCO3 38 mmol/L

(c) pH 7.38, PaCO2 60 mmHg, HCO3 34 mmol/L

(d) pH 7.15, PaCO2 50 mmHg, HCO3 16 mmol/L

Model Answer:

(a) pH 7.32, PaCO2 25 mmHg, HCO3 12 mmol/L

Primary disorder: Metabolic acidosis (low pH, low HCO3)

Expected PaCO2 (Winter's formula): = (1.5 × 12) + 8 ± 2 = 26 ± 2 = 24-28 mmHg

Measured PaCO2: 25 mmHg (within expected range)

Conclusion: Simple metabolic acidosis with appropriate respiratory compensation. No mixed disorder.

---

(b) pH 7.52, PaCO2 48 mmHg, HCO3 38 mmol/L

Primary disorder: Metabolic alkalosis (high pH, high HCO3)

Expected PaCO2: For metabolic alkalosis, PaCO2 rises ~0.7 mmHg per 1 mmol/L increase in HCO3 ΔHCO3 = 38 - 24 = 14 mmol/L Expected ΔPaCO2 = 0.7 × 14 = 9.8 mmHg Expected PaCO2 = 40 + 9.8 = 49.8 mmHg (compensation limited to ~55 mmHg)

Measured PaCO2: 48 mmHg (close to expected 49.8)

Conclusion: Simple metabolic alkalosis with appropriate respiratory compensation. No mixed disorder.

---

(c) pH 7.38, PaCO2 60 mmHg, HCO3 34 mmol/L

Primary disorder: The pH is normal, but both PaCO2 and HCO3 are elevated. This suggests either:

• Fully compensated respiratory acidosis, OR
• Mixed respiratory acidosis + metabolic alkalosis

Analysis of chronic respiratory acidosis compensation: For chronic respiratory acidosis, HCO3 rises by 3.5-4 mEq/L per 10 mmHg rise in PaCO2 ΔPaCO2 = 60 - 40 = 20 mmHg Expected ΔHCO3 = 3.5-4 × 2 = 7-8 mmol/L Expected HCO3 = 24 + 7-8 = 31-32 mmol/L

Measured HCO3: 34 mmol/L (slightly higher than expected)

Conclusion: This could represent:

1. Chronic respiratory acidosis with near-complete compensation, OR
2. Mixed chronic respiratory acidosis + mild metabolic alkalosis (HCO3 slightly higher than expected)

Clinical context is essential. If this patient has COPD and is on diuretics, the mixed disorder explanation is likely. If they have COPD alone without diuretics, this is likely compensated chronic respiratory acidosis.

---

(d) pH 7.15, PaCO2 50 mmHg, HCO3 16 mmol/L

Primary disorder: Severe acidemia with both low HCO3 (metabolic component) and elevated PaCO2 (respiratory component)

Expected PaCO2 for metabolic acidosis (Winter's formula): = (1.5 × 16) + 8 ± 2 = 32 ± 2 = 30-34 mmHg

Measured PaCO2: 50 mmHg (significantly higher than expected)

Conclusion: Mixed metabolic acidosis AND respiratory acidosis.

This is a dangerous combination - the patient has metabolic acidosis (likely from sepsis, DKA, or other cause) but is unable to compensate adequately due to respiratory failure. The very low pH of 7.15 reflects this dual insult.

This patient is at high risk of clinical deterioration and may require:

• Intubation and mechanical ventilation to correct the respiratory component
• Treatment of underlying metabolic cause
• Possibly bicarbonate therapy given severity

---

Summary Table: Compensation Rules

---

Clinical Pearls for CICM Examination

1. Always correct the anion gap for albumin - ICU patients are almost universally hypoalbuminemic

2. A normal pH doesn't mean normal acid-base status - calculate the anion gap to detect hidden HAGMA

3. The delta ratio unmasks hidden disorders - ratio greater than 2 suggests metabolic alkalosis with HAGMA

4. Lactate interpretation requires context - Type B causes exist even with normal hemodynamics

5. Respiratory compensation has physiological limits - PaCO2 rarely falls below 10-15 mmHg or rises above 55 mmHg

6. Stewart approach explains what traditional approach cannot - particularly hyperchloremic acidosis and hypoalbuminemia effects

7. BICAR-ICU changed practice - bicarbonate has a role in severe acidemia with AKI

8. D-lactate is unmeasured by standard assays - consider in short bowel syndrome with neurological symptoms

9. Mixed disorders are common in ICU - always complete the full systematic analysis

10. Treatment priorities: Address the underlying cause first; supportive correction of pH is secondary